135 related articles for article (PubMed ID: 38287797)
21. Clinical Validity of Next-Generation Sequencing Multi-Gene Panel Testing for Detecting Pathogenic Variants in Patients With Hereditary Breast-Ovarian Cancer Syndrome.
Yoo J; Lee GD; Kim JH; Lee SN; Chae H; Han E; Kim Y; Kim M
Ann Lab Med; 2020 Mar; 40(2):148-154. PubMed ID: 31650731
[TBL] [Abstract][Full Text] [Related]
22. [Molecular Diagnosis and Treatment of HBOC Syndrome].
Miki Y
Gan To Kagaku Ryoho; 2017 Feb; 44(2):102-106. PubMed ID: 28223667
[TBL] [Abstract][Full Text] [Related]
23. Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer.
Öfverholm A; Törngren T; Rosén A; Arver B; Einbeigi Z; Haraldsson K; Ståhlbom AK; Kuchinskaya E; Lindblom A; Melin B; Paulsson-Karlsson Y; Stenmark-Askmalm M; Tham E; von Wachenfeldt A; Kvist A; Borg Å; Ehrencrona H
BMC Cancer; 2023 Aug; 23(1):738. PubMed ID: 37563628
[TBL] [Abstract][Full Text] [Related]
24. Screening of
Montalban G; Bonache S; Moles-Fernández A; Gisbert-Beamud A; Tenés A; Bach V; Carrasco E; López-Fernández A; Stjepanovic N; Balmaña J; Diez O; Gutiérrez-Enríquez S
J Med Genet; 2019 Feb; 56(2):63-74. PubMed ID: 30472649
[TBL] [Abstract][Full Text] [Related]
25. Landscape of pathogenic variations in a panel of 34 genes and cancer risk estimation from 5131 HBOC families.
Castéra L; Harter V; Muller E; Krieger S; Goardon N; Ricou A; Rousselin A; Paimparay G; Legros A; Bruet O; Quesnelle C; Domin F; San C; Brault B; Fouillet R; Abadie C; Béra O; Berthet P; ; Frébourg T; Vaur D
Genet Med; 2018 Dec; 20(12):1677-1686. PubMed ID: 29988077
[TBL] [Abstract][Full Text] [Related]
26. Comparison of Optical Genome Mapping With Conventional Diagnostic Methods for Structural Variant Detection in Hematologic Malignancies.
Shim Y; Koo YK; Shin S; Lee ST; Lee KA; Choi JR
Ann Lab Med; 2024 Jul; 44(4):324-334. PubMed ID: 38433573
[TBL] [Abstract][Full Text] [Related]
27. Ovarian Cancer-Specific
Schouten PC; Richters L; Vis DJ; Kommoss S; van Dijk E; Ernst C; Kluin RJC; Marmé F; Lips EH; Schmidt S; Scheerman E; Prieske K; van Deurzen CHM; Burges A; Ewing-Graham PC; Dietrich D; Jager A; de Gregorio N; Hauke J; du Bois A; Nederlof PM; Wessels LF; Hahnen E; Harter P; Linn SC; Schmutzler RK
Clin Cancer Res; 2021 Dec; 27(23):6559-6569. PubMed ID: 34593530
[TBL] [Abstract][Full Text] [Related]
28. Prognosis of BRCA1/2-negative breast cancer patients with HBOC risk factors compared with sporadic breast cancer patients without HBOC risk factors.
Ryu JM; Nam SJ; Kim SW; Lee JE; Chae BJ; Lee SK; Yu J
Jpn J Clin Oncol; 2020 Feb; 50(2):104-113. PubMed ID: 31926487
[TBL] [Abstract][Full Text] [Related]
29. BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
Alemar B; Gregório C; Herzog J; Matzenbacher Bittar C; Brinckmann Oliveira Netto C; Artigalas O; Schwartz IVD; Coffa J; Alves Camey S; Weitzel J; Ashton-Prolla P
PLoS One; 2017; 12(11):e0187630. PubMed ID: 29161300
[TBL] [Abstract][Full Text] [Related]
30. Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis.
Yoshida R
Breast Cancer; 2021 Nov; 28(6):1167-1180. PubMed ID: 32862296
[TBL] [Abstract][Full Text] [Related]
31. Ready to clone: CNV detection and breakpoint fine-mapping in breast and ovarian cancer susceptibility genes by high-resolution array CGH.
Hackmann K; Kuhlee F; Betcheva-Krajcir E; Kahlert AK; Mackenroth L; Klink B; Di Donato N; Tzschach A; Kast K; Wimberger P; Schrock E; Rump A
Breast Cancer Res Treat; 2016 Oct; 159(3):585-90. PubMed ID: 27581129
[TBL] [Abstract][Full Text] [Related]
32. Next-Generation Sequencing-Based Detection of Germline Copy Number Variations in BRCA1/BRCA2: Validation of a One-Step Diagnostic Workflow.
Schmidt AY; Hansen TVO; Ahlborn LB; Jønson L; Yde CW; Nielsen FC
J Mol Diagn; 2017 Nov; 19(6):809-816. PubMed ID: 28822785
[TBL] [Abstract][Full Text] [Related]
33. Assessment of the functional impact of germline BRCA1/2 variants located in non-coding regions in families with breast and/or ovarian cancer predisposition.
Dos Santos ES; Caputo SM; Castera L; Gendrot M; Briaux A; Breault M; Krieger S; Rogan PK; Mucaki EJ; Burke LJ; ; Bièche I; Houdayer C; Vaur D; Stoppa-Lyonnet D; Brown MA; Lallemand F; Rouleau E
Breast Cancer Res Treat; 2018 Apr; 168(2):311-325. PubMed ID: 29236234
[TBL] [Abstract][Full Text] [Related]
34. Significance of prostate/pancreatic/skin cancer family history for detecting BRCA2 pathogenic variant careers among patients with breast cancer.
Minoura Y; Takahashi M; Maeda H; Kuwahara S; Tachikawa H; Yamamoto M; Tomioka N; Watanabe K; Sakurai A
Breast Cancer; 2022 Sep; 29(5):808-813. PubMed ID: 35641852
[TBL] [Abstract][Full Text] [Related]
35. Breast cancer in East Africa: Prevalence and spectrum of germline SNV/indel and CNVs in BRCA1 and BRCA2 genes among breast cancer patients in Tanzania.
Rweyemamu LP; Gültaşlar BK; Akan G; Dharsee N; Namkinga LA; Lyantagaye SL; Yazıcı H; Atalar F
Cancer Med; 2023 Feb; 12(3):3395-3409. PubMed ID: 35908255
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive mutation detection of BRCA1/2 genes reveals large genomic rearrangements contribute to hereditary breast and ovarian cancer in Chinese women.
Cao WM; Zheng YB; Gao Y; Ding XW; Sun Y; Huang Y; Lou CJ; Pan ZW; Peng G; Wang XJ
BMC Cancer; 2019 Jun; 19(1):551. PubMed ID: 31174498
[TBL] [Abstract][Full Text] [Related]
37. Prevalence of germline variants in consensus moderate-to-high-risk predisposition genes to hereditary breast and ovarian cancer in BRCA1/2-negative Brazilian patients.
Gomes R; Spinola PDS; Brant AC; Matta BP; Nascimento CM; de Aquino Paes SM; Bonvicino CR; Dos Santos ACE; Moreira MAM
Breast Cancer Res Treat; 2021 Feb; 185(3):851-861. PubMed ID: 33128190
[TBL] [Abstract][Full Text] [Related]
38. BRCA1 and BRCA2 whole cDNA analysis in unsolved hereditary breast/ovarian cancer patients.
Montalban G; Bonache S; Bach V; Gisbert-Beamud A; Tenés A; Moles-Fernández A; López-Fernández A; Carrasco E; Balmaña J; Diez O; Gutiérrez-Enríquez S
Cancer Genet; 2021 Nov; 258-259():10-17. PubMed ID: 34237702
[TBL] [Abstract][Full Text] [Related]
39. Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients.
Rodríguez-Balada M; Roig B; Melé M; Albacar C; Serrano S; Salvat M; Querol M; Borràs J; Martorell L; Gumà J
Clin Biochem; 2020 Feb; 76():17-23. PubMed ID: 31786208
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of hereditary breast and ovarian cancer (HBOC) predisposition gene mutations among 882 HBOC high-risk Chinese individuals.
Shao D; Cheng S; Guo F; Zhu C; Yuan Y; Hu K; Wang Z; Meng X; Jin X; Xiong Y; Chai X; Li H; Zhang Y; Zhang H; Liu J; Ye M
Cancer Sci; 2020 Feb; 111(2):647-657. PubMed ID: 31742824
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
